Astellas Pharma Inc. has been the center of numerous major developments lately. The company gained the FDA approval for his gastric cancer therapy indicated for advanced gastric and GEJ cancer, and unveiled new life sciences centers in Cambridge, Massachusetts and the South San Francisco Biotech Corridor. In collaboration with AviadoBio, Astellas agreed on an exclusive license for gene therapy AVB-101 aimed at Frontotemporal Dementia with a deal worth over $2.2bn. The company is undergoing management structure revision, and also announced a collaborative agreement with Mass General Brigham. Both the European Commission and U.S. FDA approved PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for the first-line treatment of advanced bladder cancer. Moreover, their digital health solution for heart failure management got FDA listing. Astellas is facing controversy too, with a layoff announcement at one of their biomanufacturing facilities and an employee indictment in China. Lastly, their commitment to local community healthcare is evident in their initiatives in Tanzania and an exciting new partnership with YASKAWA focused on the integration of pharmaceutical and robotics technologies for cell therapy.
Astellas Pharma Inc. News Analytics from Mon, 11 Oct 2021 07:00:00 GMT to Fri, 18 Oct 2024 22:31:03 GMT -
Rating 8
- Innovation 7
- Information 10
- Rumor 8
